INCATE awards PhalconBio Stage II Funding to advance Dual-Action Phages for severe bacterial pneumonia
Allschwil, Switzerland - INCATE, the Incubator for Antimicrobial Therapies in [...]
From discussion to discovery: meet INCATE’s new Stage I ventures
For the first time, INCATE’s Selection Committee didn’t simply meet [...]
Building momentum: recent milestones at Obulytix
Obulytix has had an exciting start to the year, marked [...]
Big ideas, bold solutions: inside the 10th AMR Conference
The 10th AMR Conference in Basel once again brought together [...]
INCATE and Cystic Fibrosis Foundation Collaborate to Combat Antimicrobial Resistance
February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), [...]
Introducing new Stage I ventures
The INCATE Selection Committee has selected five promising ventures to [...]
INCATE appoints first Chief Executive Officer to shape its future vision
February 3, 2026 — INCATE (INCubator for Antibacterial Therapies in [...]
The Finalists for the Startup Pitch Event 2026 are in!
Every year, selecting the finalists for the Startup Pitch Event [...]
JPMA and INCATE join forces to Advance Innovation in the Fight Against Antimicrobial Resistance
January 21, 2026 – The Japan Pharmaceutical Manufacturers Association (JPMA) [...]
Basilea joins INCATE to support antifungal innovation
January 13, 2026 — INCATE (INCubator for Antibacterial Therapies in [...]
